The Indian government on Monday approved Kalydeline, an Indian drug developed by Biogen Idec, for the treatment of acne and hyperpigmentation in the Asian region.
The approval, announced in a statement, comes amid growing concern that the drug may worsen the spread of the pandemic.
It marks the first time the country has approved a drug for treating the condition.
“It is a breakthrough for our country.
This drug is an innovative, affordable, effective and reliable option for treating acne and other skin disorders,” Indian Prime Minister Narendra Modi said in a news conference after the announcement.”
The Indian government’s announcement of the approval of Kalydline marks a new era in Indian health care, which has been dominated by expensive, expensive, costly drugs,” Modi said.”
This will be an exciting and transformative opportunity for Indian health system, for Indian society, for people of India and for the entire world.”
Kalydeca is made by Biogenesis and will be sold in India through several generic and specialty drug stores.
The drug will cost about $6,000 for a 60-day supply.
It is not the first drug to be approved in India for treating hyperpigeonosis, a condition in which the pigment cells in the skin’s surface begin to darken, a disease that can lead to severe skin and eye disorders.
The virus that causes hyperpigo also causes hyperpalpigioidosis, an overgrowth of pigment cells, which can lead eventually to skin cancer.
Kalyde, developed by a team of scientists led by scientists from the Indian Institute of Technology, Jaipur, was approved by the Food and Drug Administration in 2014.
It was the first-ever drug approved by an Indian government for treating pheochromocytoma, a cancer that affects skin.
The drug was first approved by Japan in 2002 for treating people with a rare form of the disease known as non-Hodgkin’s lymphoma.
It has since been approved by a number of other countries.
The FDA also approved Kiyoharu in 2012 for treating anorexia nervosa, an eating disorder.
Kiyohar was approved in the U.S. in 2010.
The agency did not immediately respond to a request for comment on the approval in India.